从印度真实世界数据看 Yukon Choice Flex 西罗莫司洗脱冠状动脉支架的长期安全性和有效性。
Long term safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent-a real-world data from India.
机构信息
Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India.
Department of Cardiology, Vardhman Mahavir Medical College, New Delhi, 110029, India.
出版信息
Indian Heart J. 2021 Nov-Dec;73(6):733-736. doi: 10.1016/j.ihj.2021.09.006. Epub 2021 Sep 10.
Abstract
In-stent restenosis and stent thrombosis are the major concerns while choosing a coronary stent. This single-centre, retrospective study evaluated the one and three-year clinical outcomes following implantation of Yukon Choice Flex (YCF) sirolimus-eluting stent. A total of 168 consecutive patients with 217 lesions underwent stenting with YCF stent. The presentation was with acute coronary syndrome in 158 (94%) patients. At 3 years, 9 (5.3%) patients died due to cardiac cause. Myocardial infarction, and definite stent thrombosis occurred in 10 (6%) and 4 (2.4%) patients respectively. Redo stenting and coronary artery bypass surgery was performed in 3 (1.8%) and 1 (0.6%) patient respectively. The use of YCF sirolimus eluting stent was associated with a favourable safety and efficacy profile at one and three-years of follow-up in a high-risk population.
摘要
支架内再狭窄和支架内血栓形成是选择冠状动脉支架时的主要关注点。本单中心回顾性研究评估了 Yukon Choice Flex（YCF）西罗莫司洗脱支架植入后的一年和三年临床结果。共有 168 例连续患者的 217 处病变接受了 YCF 支架置入。表现为急性冠状动脉综合征的患者有 158 例（94%）。3 年后，因心脏原因死亡的患者有 9 例（5.3%）。心肌梗死和明确的支架内血栓形成分别发生在 10 例（6%）和 4 例（2.4%）患者中。再次血运重建和冠状动脉旁路移植术分别在 3 例（1.8%）和 1 例（0.6%）患者中进行。在高危人群中，YCF 西罗莫司洗脱支架的使用在一年和三年随访时具有良好的安全性和疗效。
相似文献
1
Long term safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent-a real-world data from India.从印度真实世界数据看 Yukon Choice Flex 西罗莫司洗脱冠状动脉支架的长期安全性和有效性。
Indian Heart J. 2021 Nov-Dec;73(6):733-736. doi: 10.1016/j.ihj.2021.09.006. Epub 2021 Sep 10.
2
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.Yukon Choice Flex西罗莫司洗脱冠状动脉支架在所有患者人群队列中的安全性和有效性。
Indian Heart J. 2014 May-Jun;66(3):345-9. doi: 10.1016/j.ihj.2014.05.003.
3
Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent.与紫杉醇洗脱 Taxus 支架相比，雷帕霉素洗脱 Yukon-choice 支架冠状动脉植入 12 个月后再狭窄率增加。
Clin Cardiol. 2010 Apr;33(4):E33-8. doi: 10.1002/clc.20483.
4
Incidence of adverse cardiac events 5 years after polymer-free sirolimus eluting stent implantation: Results from the prospective Bad Berka Yukon Choice™ registry.无聚合物西罗莫司洗脱支架植入术后5年不良心脏事件的发生率：前瞻性巴特贝卡育空选择™注册研究结果
Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1080-6. doi: 10.1002/ccd.25272. Epub 2013 Nov 12.
5
Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.随机比较无聚合物西罗莫司洗脱支架与聚合物紫杉醇洗脱支架在糖尿病患者中的应用：LIPSIA Yukon 试验。
JACC Cardiovasc Interv. 2011 Apr;4(4):452-9. doi: 10.1016/j.jcin.2010.11.016.
6
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.紫杉醇洗脱支架与西罗莫司洗脱支架治疗西罗莫司洗脱支架内再狭窄的随机试验：ISAR-DESIRE 2（冠状动脉支架置入术和血管造影结果：药物洗脱支架治疗支架内再狭窄 2）研究。
J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.
7
Three-Year Outcomes of Biodegradable Polymer-Coated Ultra-Thin (60 µm) Sirolimus-Eluting Stents in Real-World Clinical Practice.在真实临床实践中，生物可降解聚合物涂层超薄（60μm）西罗莫司洗脱支架的 3 年结果。
Ann Acad Med Singap. 2019 May;48(5):150-155.
8
Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).糖尿病患者中无聚合物西罗莫司洗脱支架与聚合物载紫杉醇洗脱支架随机比较的 5 年临床随访（LIPSIA Yukon 试验）。
Catheter Cardiovasc Interv. 2014 Feb 15;83(3):418-24. doi: 10.1002/ccd.25131. Epub 2013 Aug 9.
9
Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.雷帕霉素洗脱支架和球囊血管成形术治疗雷帕霉素洗脱支架内再狭窄的安全性和有效性。
Cardiovasc Revasc Med. 2015 Mar;16(2):84-9. doi: 10.1016/j.carrev.2015.01.004. Epub 2015 Jan 29.
10
A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.在完全闭塞的冠状动脉中，与含永久性聚合物的依维莫司洗脱支架相比，杂交型西罗莫司洗脱支架与含可生物吸收聚合物的依维莫司洗脱支架的随机多中心比较：原发性闭塞性原生冠状动脉支架置入术 IV 研究的原理和设计。
Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240.
引用本文的文献
1
Evaluate the Quality of Life in Patients With Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft.评估经皮冠状动脉介入治疗与冠状动脉旁路移植术患者的生活质量。
Cureus. 2024 Jan 20;16(1):e52645. doi: 10.7759/cureus.52645. eCollection 2024 Jan.
2
Acute Myocardial Infarction-Related Hospitalizations in Non-elderly Patients with Pneumonia: a Population-Based Study.非老年肺炎患者急性心肌梗死相关住院情况：一项基于人群的研究。
SN Compr Clin Med. 2023;5(1):160. doi: 10.1007/s42399-023-01499-9. Epub 2023 Jun 7.
3
Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents.载有依维莫司的超薄支架治疗动脉粥样硬化病变：最长支架亚组分析的 3 年随访结果
Indian Heart J. 2023 Jul-Aug;75(4):279-284. doi: 10.1016/j.ihj.2023.03.006. Epub 2023 Mar 25.
4
Role of fibrinogen, albumin and fibrinogen to albumin ratio in determining angiographic severity and outcomes in acute coronary syndrome.纤维蛋白原、白蛋白及纤维蛋白原与白蛋白比值在确定急性冠状动脉综合征血管造影严重程度及预后中的作用。
World J Cardiol. 2023 Jan 26;15(1):13-22. doi: 10.4330/wjc.v15.i1.13.
本文引用的文献
1
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
2
Improved short and long term survival associated with percutaneous coronary intervention in the elderly patients with acute coronary syndrome.经皮冠状动脉介入治疗与老年急性冠状动脉综合征患者的短期和长期生存改善相关。
BMC Geriatr. 2018 Jun 7;18(1):137. doi: 10.1186/s12877-018-0818-z.
3
Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study.药物洗脱支架与裸金属支架冠状动脉介入治疗患者临床结局的比较：一项全国性人群研究。
Acta Cardiol Sin. 2017 Jan;33(1):10-19. doi: 10.6515/acs20160608a.
4
Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment.理解与管理支架内再狭窄：从发病机制到治疗的临床数据综述
J Thorac Dis. 2016 Oct;8(10):E1150-E1162. doi: 10.21037/jtd.2016.10.93.
5
Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trial.生物可降解聚合物涂层西罗莫司洗脱支架治疗ST段抬高型心肌梗死与非ST段抬高型急性冠状动脉综合征的五年结局：CREATE试验的见解
J Cardiol. 2017 Jan;69(1):149-155. doi: 10.1016/j.jjcc.2016.02.012. Epub 2016 Mar 10.
6
One-year Mortality after an Acute Coronary Event and its Clinical Predictors: The ERICO Study.急性冠脉事件后的一年死亡率及其临床预测因素：ERICO研究。
Arq Bras Cardiol. 2015 Jul;105(1):53-64. doi: 10.5935/abc.20150044. Epub 2015 May 8.
7
Stent thrombosis: a clinical perspective.支架血栓形成：临床观点。
JACC Cardiovasc Interv. 2014 Oct;7(10):1081-92. doi: 10.1016/j.jcin.2014.05.016.
8
Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study.急性冠脉综合征患者出院后一年死亡率的预测因素：来自EPICOR（急性冠状动脉综合征患者抗栓治疗模式的长期随访）研究的新风险评分。
Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):509-17. doi: 10.1177/2048872614554198. Epub 2014 Oct 9.
9
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.Yukon Choice Flex西罗莫司洗脱冠状动脉支架在所有患者人群队列中的安全性和有效性。
Indian Heart J. 2014 May-Jun;66(3):345-9. doi: 10.1016/j.ihj.2014.05.003.
10
Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.裸金属支架、第一代药物洗脱支架和第二代药物洗脱支架的支架血栓形成风险：来自 18334 名患者的注册研究结果。
JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74. doi: 10.1016/j.jcin.2013.06.015.
Zotero 插件